izpis_h1_title_alt

Modificirane dendritične celice kot cepivo proti raku
ID Pungert, Tjaša (Author), ID Narat, Mojca (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (792,23 KB)
MD5: 269BFD5AB762AD3087099E8056591ADB

Abstract
Dendritične celice so pogosto imenovane glavne antigen-predstavitvene celice in so ključne za pravilno delovanje imunskega sistema v človeškem telesu. Razvoj rakavega obolenja običajno vodi v zaviranje delovanja bolnikovih dendritičnih celic. Modifikacija dendritičnih celic v pogojih ex vivo pa omogoča ohranitev njihovega delovanja in ob oblikovanju celic v cepivo tudi enostavno odmerjanje pacientu. Modifikacija dendritičnih celic obsega obleganje primernega antigena, dozorevanje dendritičnih celic in predstavljanje vnesenega antigena, kar dodatno izboljša njihovo učinkovitost. Zrele dendritične celice je potrebno oblikovati v cepivo, pri čemer je potrebno upoštevati mesto in način odmerjanja cepiva, razmisliti o velikosti odmerka ter morebitnem dodatku adjuvansa. Na uspeh modifikacije vplivajo številni dejavniki, med drugimi podtip uporabljenih dendritičnih celic, izvor izbranega antigena, njegova količina ter izbira adjuvansa. Na uspeh cepiva vpliva stopnja razvoja rakavega obolenja, velikost odmerka, urnik cepljenja, način odmerjanja cepiva ter splošno imunološko stanje pacienta. Obstaja veliko pristopov modifikacije dendritičnih celic ex vivo, a trenutno še ni znano, kateri je najučinkovitejši. Vnos modificiranih dendritičnih celic bi v idealnih pogojih rezultiral v uspešni migraciji modificiranih dendritičnih celic v limfatična tkiva, močni aktivaciji naivnih celic T ter močnem in specifičnem imunskem odzivu proti rakavim celicam. Zaželen je tudi nastanek spominskih celic, ki bi bolnika ščitile pred ponovnim pojavom rakavega obolenja. Trenutno obstaja več cepiv na podlagi ex vivo modificiranih celic, ki so dovoljena za uporabo v proti-rakavi terapiji.

Language:Slovenian
Keywords:Dendritične celice, modifikacija, cepivo, rak, adjuvans, terapija
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:BF - Biotechnical Faculty
Publisher:[T. Pungert]
Year:2020
PID:20.500.12556/RUL-118629 This link opens in a new window
UDC:602:57.083.3:577.27:606:616-006.6(043.2)
COBISS.SI-ID:27493123 This link opens in a new window
Publication date in RUL:29.08.2020
Views:2799
Downloads:158
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Secondary language

Language:English
Title:Modified dendritic cells as cancer vaccine
Abstract:
Dendritic cells are often called professional antigen presenting cells and are crucial for human immune system. The development of cancer usually causes immunosuppression of dendritic cells. But modification of dendritic cells in ex vivo conditions allows them to keep their function and formation into a vaccine makes their application to a patient easily realisable. Modification of dendritic cells includes loading them with a suitable antigen and fallowed up maturation to further improve their function. Mature dendritic cells need to be formulated into a vaccine. At this stage the site of application, dose volume and the need for an adjuvant need to be considered. The success of maturation depends on numerous factors, including the used dendritic cell subtype, cancer progression, antigen used, the quantity of antigen, adjuvant used, dose volume, vaccination schedule, route of administration and overall patients’ immune condition. There are many approaches to dendritic cell modification, but it is not clear which one results in highest efficiency. The use of modified dendritic cells would ideally result in successful migration to lymph nodes, strong T cell activation and strong and selective immune response against cancer cells. The emergence of memory T cells is also desirable to protect the patient from disease relapse. Currently there are few vaccines based on ex vivo modified dendritic cells approved for use in cancer immunotherapy.

Keywords:Dendritic cells, modification, vaccine, cancer, adjuvant, therapy

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back